Clinical trials: Controlled Diabetes
- Condition Controlled Diabetes
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Diabetes Mellitis Type 2
A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects
This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic…
- Trial name
- NCT00961025
- Testing
- DA-1229
- Where
- South Korea
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Dong-A Pharmaceutical Co., Ltd.
Prediabetes, Normoglycemic
Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile, Gastric Emptying and GLP-1 Release in Normoglycemic and Prediabetic Subjects
Aim of the study is to investigate the postprandial response on blood glucose, insulin, C-peptide, incretin response and gastric emptying after intake of collagen hydrolysate compared to placebo in normoglycemic and in…
- Trial name
- NCT06789263
- Testing
- Collagen hydrolyzed peptides
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rousselot BVBA
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes Mellitus
FTIH of ECC5004 in Healthy and Diabetic Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus
- Trial name
- NCT05654831
- Testing
- ECC5004
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Eccogene
Diabetes
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy…
- Trial name
- NCT06829563
- Testing
- RZ-629, Fasted, Fed
- Where
- Australia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Rezubio Pharmaceuticals Co., Ltd.
Type 2 Diabetes Mellitus
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human (FIH) study to evaluate the safety, tolerability, food effect (FE), pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered XW014 in…
- Trial name
- NCT05579314
- Testing
- XW014
- Where
- 3 sites in United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences USA Co., Ltd.
Type 2 Diabetes Mellitus
Safety Study of ISIS 325568 in Healthy Volunteers
The primary purpose of this trial is to assess the safety of ISIS 325568 when given at increasing single doses and to assess the safety of the same doses when given multiple times.
- Trial name
- NCT00519727
- Testing
- ISIS 325568
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetic Foot Ulcer, Ulcer Foot
Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC dressings treatments for Diabetic Foot Wounds
- Conditions
- Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
- Trial name
- NCT03398538
- Testing
- Offloading, Additional (outer) Dressing Application, Mirragen Wound Matrix Dressing
- Where
- 5 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- ETS Wound Care, LLC
Diabetic Foot Ulcer
Omega3 Wound Fish Skin Graft in the Treatment of DFUs
The purpose of this clinical evaluation is to collect patient outcome data on a commercially available 510K FDA-approved product that is derived from minimal processing of Atlantic cod fish skin: KerecisTM Omega3 Wound.
- Trial name
- NCT04133493
- Testing
- Kerecis Omega3 Wound, Fibracol
- Where
- 5 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kerecis Ltd.
Type 2 Diabetes Mellitus
NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
The primary objective of this trial is to evaluate the safety and tolerability of multiple intravenous doses of NOX-E36 in healthy subjects and patients with type 2 diabetes mellitus.
- Trial name
- NCT01085292
- Testing
- NOX-E36
- Where
- 5 sites in Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- TME Pharma AG
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Obesity & Overweight, Circadian Rhythm Disorders
Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers
Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns.
- Conditions
- Obesity & Overweight, Circadian Rhythm Disorders, Gut Microbiota Modulation, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
- Trial name
- Shift2Health (NCT07440147)
- Testing
- Verum (A)
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Obesity
Effect of LAPS-Exendin on Body Weight in Obese Population
The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
- Trial name
- NCT02075281
- Testing
- HM11260C
- Where
- United States
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus (T2DM)
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.
- Trial name
- NCT01407003
- Testing
- LIK066
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
The study will comprise primarily a single-ascending dose (SAD) escalation component.
- Trial name
- NCT03970122
- Testing
- GFB-887
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Type 2 Diabetes Mellitus
Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human
This study was designed as a single-center, single-arm, open, fixed-sequence, self-controlled trial in healthy subjects.
- Trial name
- NCT06495931
- Testing
- HRS-1780 tablets, HR20033 tablets, HRS-7535 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes
A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects
To evaluate the pharmacokinetics similarity between the 14028 injection produced by Sunshine Lake Pharma Co., Ltd. and dulaglutide injection (TRULICITY®) produced by Eli Lilly and Company for single dose in healthy male subjects…
- Trial name
- NCT05459285
- Testing
- 14028 injection, dulaglutide injection
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Diabetes Mellitus
Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart
A study evaluating the safety of a high and low dose of PPM-204 on the electrical pathways of the heart.
- Trial name
- NCT00447629
- Testing
- PPM-204
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetes
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)
The purpose of this study is to evaluate the safety, tolerability and effect on blood glucose control of BMS-903452 compared to placebo in healthy subjects \& relative bioavailability of the crystalline and amorphous forms of…
- Trial name
- NCT01240980
- Testing
- BMS-903452
- Where
- 2 sites in United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Obesity, Type 2 Diabetes Mellitus
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05184322
- Testing
- T2026, Oral ecnoglutide tablet
- Where
- Australia
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.